Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News
Zanubrutinib looks ‘robust’ in Waldenström macroglobulinemia
- Author:
- Jennifer Smith
Phase 1 data shows a high overall response rate to the BTK inhibitor.
News
Variant not linked to CLL in Southeast Europe
- Author:
- Jennifer Smith
DUBROVNIK, CROATIA – The PTPN22 R620W polymorphism was not associated with CLL in patients from Southeast Europe.
News
FDA approves elotuzumab with pom/dex in refractory myeloma
- Author:
- Jennifer Smith
The approval is based on results from the phase 2 ELOQUENT-3 trial.
News
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
- Author:
- Jennifer Smith
Sandoz has decided not to pursue U.S. approval for its rituximab product (GP2013), a proposed biosimilar of...
News
FDA approves second pegfilgrastim biosimilar
- Author:
- Jennifer Smith
Pegfilgrastim-cbqv, previously known as CHS-1701, will be marketed as Udenyca by Coherus BioSciences.
News
Novel risk factors for febrile neutropenia in NHL, solid tumors
- Author:
- Jennifer Smith
Corticosteroid use was most strongly associated with chemotherapy-induced febrile neutropenia.
News
FDA expands approval of pembrolizumab in NSCLC
- Author:
- Jennifer Smith
Pembrolizumab is now approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of...
News
Ruxolitinib receives priority review for acute GVHD
- Author:
- Jennifer Smith
Ruxolitinib is under review as a treatment for patients with acute graft-versus-host disease who have had an inadequate response to...
News
OMS721 gains orphan designation for HSCT-associated thrombotic microangiopathy
- Author:
- Jennifer Smith
Early results from a phase 2 trial suggest OMS721 can be effective against HSCT-TMA.
News
When to choose stem cell transplant in PTCL
- Author:
- Jennifer Smith
DUBROVNIK, CROATIA – Dr. Ali Bazarbachi gives his tips for when to use allo- versus auto-HSCT in patients with peripheral T-cell lymphomas.
News
CDK8 inhibitor shows activity against AML
- Author:
- Jennifer Smith
DUBROVNIK, CROATIA – SEL120 looks active against acute myeloid leukemia in preclinical work, but experts aren’t sure why.
News
When is it CMML?
- Author:
- Jennifer Smith
DUBROVNIK, CROATIA – Dr. Nadira Durakovic offers her tips for differentiating between CMML and other look-alike disorders.
News
FDA offers guidance on MRD assessment in blood cancer trials
- Author:
- Jennifer Smith
The draft guidance document provides advice to industry on how to use minimal residual disease as a biomarker in clinical trials of hematologic...
News
Optimizing use of TKIs in chronic leukemia
- Author:
- Jennifer Smith
DUBROVNIK, CROATIA – Dr. Hagop M. Kantarjian offers tips for choosing the best TKI when treating patients with CML.
News
Updated ThroLy system predicts need for thromboprophylaxis
- Author:
- Jennifer Smith
DUBROVNIK, CROATIA – The revised ThroLy scoring system offers a lymphoma-specific system to predict thromboembolic events.